 Initiation of a phase 3 program open-label extension study using Simufilam for patients with Alzheimers Disease is expected in 2nd half of 2022. An ongoing long-term open label study, initiated in March of 2020 is ongoing; Dosing completion is expected Q4 of 2022 and results from it are expected before end of 2022. 